Since ESR1 mutations drive super-enhancer–mediated transcriptional reprogramming in ER+ breast cancer cells (11), we hypothesized that the transcriptional activity of ESR1 mutants is likewise dependent on BRD4. The gene discussed is BRD4; the disease is breast carcinoma.